Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.

Breast Cancer Research and Treatment
D Gareth EvansAnthony Howell

Abstract

The aim of this study is to delineate more clearly the prevalence of HER2+ breast cancer in women with germline BRCA1/2 mutations. For this purpose, we analysed primary mutation screens on women with breast cancer with unequivocal HER2 amplification and assessed the proportion of BRCA1 and BRCA2 breast cancers that were HER2+ comparing this with the existing literature. The results are that 1063 primary BRCA screens had confirmed tumour HER2 status. If HER2+ only 2.5 % (4/156) and 3.2 % (5/156) of women had a BRCA1 or BRCA2 mutation identified respectively; compared to 27.7 % (115/415) and 8.2 % (34/415) with triple negative tumours. Only 2.1 % (4/195) women with BRCA1-related breast cancer had HER2 amplified breast cancers rising to 6.8 % (n = 12, p = 0.04) in BRCA2. These rates are in keeping with most of the existing literature except a recent large multicenter report which documented higher rates but with no control group. The study concluded that true HER2-amplified breast cancers are rare amongst BRCA1 mutation carriers and are less common in BRCA2 than background rates.

References

Mar 7, 1998·American Journal of Human Genetics·G ParmigianiO Aguilar
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas S FrankGregory C Critchfield
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sunil R LakhaniDouglas F Easton
Apr 2, 2004·Statistics in Medicine·Jonathan TyrerJack Cuzick
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sunil R LakhaniUNKNOWN Breast Cancer Linkage Consortium
Feb 16, 2008·Breast Cancer Research : BCR·Hannaleena EerolaHeli Nevanlinna
May 21, 2010·Breast Cancer Research : BCR·Nasim MavaddatAntonis C Antoniou
Sep 2, 2010·Journal of Medical Genetics·J R F WilsonD M Eccles
May 24, 2011·Breast Cancer Research and Treatment·Veronica I Lagos-JaramilloJeffrey N Weitzel
Dec 7, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Nasim MavaddatUNKNOWN Consortium of Investigators of Modifiers of BRCA1/2
Jun 1, 2013·Journal of the National Cancer Institute·Ellen CopsonUNKNOWN POSH Study Steering Group
Jun 27, 2013·BMJ : British Medical Journal·D Gareth EvansDeborah Fitzsimmons
Nov 29, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·D Gareth R EvansFiona Lalloo
Dec 19, 2013·British Journal of Cancer·A J LeeUNKNOWN Breast Cancer Association Consortium
Mar 5, 2015·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·F AloraifiJ G Geraghty
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gaëlle BougeardThierry Frebourg

❮ Previous
Next ❯

Citations

Mar 3, 2018·Current Treatment Options in Cardiovascular Medicine·Kelly C GastKathryn J Ruddy
May 27, 2020·Experimental & Molecular Medicine·Seung Hyuk ChoiKatherine A Jones
Jul 10, 2019·Molecular and Clinical Oncology·Joanna Huszno, Zofia Kolosza
Jan 21, 2021·Current Oncology·Leonor Vasconcelos de MatosFátima Vaz
Jan 16, 2021·Breast Care·Eva Valentina Klocker, Christoph Suppan
Jan 7, 2022·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Yiming GaoSamantha L Heller
Jan 28, 2022·JAMA Oncology·UNKNOWN Breast Cancer Association ConsortiumDouglas F Easton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.